Senolytics added to cancer therapy shrink tumors further in 36 mouse studies
A systematic review of 36 mouse studies finds that adding senolytics to senescence-inducing cancer treatments consistently cut tumor burden and senescence markers.
Summary
Many cancer treatments, including chemotherapy, radiation and CDK4/6 or PARP inhibitors, push some cells into senescence. In this state cells stop dividing but release inflammatory signals (the SASP) that can help tumors grow back. This systematic review identified 36 mouse studies testing whether adding a senolytic drug, which kills senescent cells, improves on the cancer treatment alone. Across 11 cancer types, the combination generally reduced tumor burden. It also lowered senescence markers and IL-6, reduced proliferation (Ki-67) and increased apoptosis (caspase-3). These are mouse data only. The review synthesized results qualitatively and did not pool effect sizes. The mechanism is worth testing in human trials; this is not yet a clinical recommendation.
Detailed Summary
Cancer therapies such as chemotherapy, radiation, castration and CDK4/6 or PARP inhibitors often work partly by forcing cells into senescence, a stable growth arrest enforced through the p53/p21 and p16INK4a/Rb axes. Those senescent cells linger and secrete the senescence-associated secretory phenotype (SASP). The SASP is a mix of cytokines and growth factors that can promote invasion, resistance and relapse. The mechanistic idea is a one-two hit: induce senescence, then clear the senescent cells with a senolytic, such as a BCL-2 family inhibitor or dasatinib with quercetin. This review asks whether that sequence beats the senescence-inducing therapy alone in living animals.
The authors followed PRISMA 2020 and a PROSPERO-registered protocol (CRD420251161998). They searched PubMed, Scopus and Web of Science through August 2025. Of 1,262 records, 568 unique articles were screened by title and abstract, and 36 murine in vivo studies were included. The included cancer types were colorectal, breast, ovarian, lung, melanoma, meningioma, prostate, head and neck, bladder, pancreatic and hepatocellular carcinoma. Eligible models could be xenograft, syngeneic or orthotopic. Risk of bias was assessed with the SYRCLE tool. The provided text does not report the breakdown of model types, group sizes, treatment durations or the specific drug pairings across included studies.
Across cancer types, senolytic co-treatment consistently reduced tumor burden compared with the senogenic therapy alone. Senescence markers (SA-β-gal, p21, p53, p16INK4a) fell in most combination groups, and IL-6 was the most consistently suppressed SASP cytokine. Ki-67 decreased and caspase-3 activation rose in most models, indicating less proliferation and more apoptosis. BCL2 downregulation and higher γ-H2AX, a DNA damage marker, appeared in several studies. The article's title states that survival can improve, but the abstract's results and conclusion do not report survival findings, and the provided text gives no survival figures.
This is evidence about mechanism and tumor control in mice, not about human outcomes or lifespan. The senescence marker changes support the proposed mechanism. Because designs, drugs, doses, schedules and outcomes varied widely, the studies were synthesized only qualitatively, with no pooled effect sizes. A favorable overall direction also does not mean every tested pairing worked. Timing, dosing and sequencing remain unresolved, and the authors call for standardized in vivo methods and translational studies before clinical use.
Key Findings
- 36 murine in vivo studies met inclusion criteria out of 1,262 records identified (568 unique articles screened after deduplication).
- Senolytic plus senogenic combinations consistently reduced tumor burden versus the senogenic therapy alone across 11 cancer types.
- Senescence markers (SA-β-gal, p21, p53, p16INK4a) decreased in the majority of combination groups.
- IL-6 was the most consistently suppressed SASP cytokine; this is a mechanistic readout, not a survival result.
- Ki-67 fell and caspase-3 activation rose across most models, indicating less proliferation and more apoptosis.
- BCL2 downregulation and γ-H2AX elevation appeared in several studies, suggesting added apoptosis and DNA damage.
- Evidence is entirely murine and synthesized qualitatively; no pooled effect sizes or pooled survival estimates are reported in the provided text.
Methodology
This was a systematic review under PRISMA 2020 with a prospectively registered PROSPERO protocol, searching three databases through August 2025. Two reviewers independently screened and extracted data, and risk of bias was rated with the SYRCLE tool across ten domains. Included studies were murine cancer models (xenograft, syngeneic or orthotopic) comparing senolytic or senomorphic plus senogenic therapy with a comparator arm. Data were synthesized qualitatively only, with the direction of marker changes recorded. No meta-analysis was performed because of heterogeneity.
Study Limitations
The authors note heterogeneity in models, drugs, doses and outcome reporting, which prevented meta-analysis. The evidence is entirely animal-based. The provided text does not report the distribution of model types (for example, immunodeficient xenograft versus immunocompetent syngeneic), group sizes or follow-up length, so immune effects and long-term toxicity cannot be judged from it. Optimal timing, dosing and sequencing remain unresolved. The provided text does not describe risk-of-bias results or conflicts of interest.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
